News | August 15, 2014

First Patient Enrollment Study of Shorter-term Dual Antiplatelet Therapy in ACS Patients With OrbusNeich Stent

REDUCE study will evaluate acute coronary syndrome patients in 30 Asian and European countries who receive the Combo Dual Therapy Stent

Patient Enrollment REDUCE Sudy Combo Dual Therapy Stent OrbusNeich

August 15, 2014 — OrbusNeich announced first patient enrollment in the Randomized Evaluation of short-term Dual anti platelet therapy in patients with acute coronary syndrome treated with the Combo Dual Therapy StEnt (REDUCE) Study. The study is designed to evaluate the potential for shorter-term dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with the Combo Dual Therapy Stent. The physician-initiated, prospective, multicenter, randomized study will enroll 1,500 patients in up to 30 centers in Asia and Europe.

Patients will be randomized in a 1:1 fashion to receive either three or 12 months of DAPT. The study’s primary endpoint is the composite of all-cause mortality, any myocardial infarction (MI), Target Vessel Revascularization (TVR), stroke and major bleeding from enrollment to 12 months.

The REDUCE study will be managed by Diagram Diagnostic Research and Management. Principal investigators are Prof. Harry Suryapranata of the Radboud University Medical Center, Nijmegen, The Netherlands; and Prof. Giuseppe de Luca of Novara Hospital, Novara, Italy. E. Kedhi, M.D., Ph.D., performed the first implant at Isala Hospital in The Netherlands.

“The dual therapy approach of the Combo Stent maintains the efficacy of monotherapy drug eluting stents while providing the benefits of accelerated stent endothelialization and healing,” said Suryapranata. “For this reason, the Combo Stent may enable us to safely reduce the duration of DAPT.”

“This would be a significant achievement, as DAPT causes a number of challenges and limitations for patients because of the potential for side effects such as significant bleeding events,” added de Luca. “The REDUCE trial is the first study to evaluate the reduction of DAPT following treatment with the Combo Stent in a randomized trial and may provide us with evidence to support the safety of three months DAPT in ACS patients.”

“The first patient enrollment in the REDUCE trial represents a critical milestone for our company, for cardiologists and for patients,” said B. Wayne Johnson, president and chief operating officer of OrbusNeich. “The trial demonstrates our commitment to taking a serious look at the ‘duration of DAPT’ question. We look forward to providing cardiologists and patients a definitive answer for how long DAPT is required with our novel approach to true arterial vessel healing.”

For more information: www.diagram-zwolle.nl.


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now